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A Reactivation of Ocular Toxoplasmosis during Pregnancy
Abstract
Background: Toxoplasma gondii is a parasite estimated to affect over 500 million people worldwide. The
feline is the definitive host for the parasite and infection may be acquired or congenital via maternal
transmission. Humans may acquire the infection by ingestion of raw or undercooked meats and
vegetables, contaminated water, or exposure to infected cat feces. The infection is often benign, selflimiting, and asymptomatic for humans, but potentially life threatening to infants or the
immunocompromised patient.
Case Report
Report: A 22 year-old Caucasian female, pregnant at 12 weeks gestation, presented to the
optometry service with acute symptoms of hazy vision and a new gray stationary blind-spot in the inferior
field of vision of the right eye. Clinical picture led to diagnosis of reactivated ocular toxoplasmosis.
Conclusion: Ocular toxoplasmosis primarily affects the retina, producing a retinochoroiditis with resultant
scarring and potential blindness. Treatment with a combination of antibiotics and steroid may be
required. Allergy history and current pregnancy were important factors to consider when determining
treatment of our patient.
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INTRODUCTION

Toxoplasmosis gondii is an intracellular parasite that affects over 36 million
people in the United States and is the second leading cause of death from foodborne
illness.1-3 It affects approximately one third of people worldwide, with the highest
prevalence in South America and Africa.1,2,4,5 Infection rates vary greatly, with high
concentrations in certain regions or cultures based on climate, food preparation,
hygiene, cat population, and general healthcare. Using the feline as the host, the
parasite can be either acquired or congenitally transmitted.
Acquired toxoplasmosis may occur by ingestion of raw or undercooked meats and
vegetables, unpasteurized milk, or water contaminated with Toxoplasma oocytes.
The infection may also be acquired via exposure to an infected feline, its feces,
contaminated litter box or soil. Less common, is the transmission during organ
transplant or blood transfusion. The acquired form of the infection in healthy
individuals often goes undetected, with flu-like symptoms being the most common
presentation. In the immunocompromised, the course may be more life-threatening
due to the risk of encephalitis, pneumonia, or myocarditis.1,6-8
Congenital toxoplasmosis occurs when the primary infection of a woman is
acquired just before or during pregnancy with transplacental transmission during
gestation. The prevalence of congenital infection has been reported as high as 1 in
10,000 live births in the United States.7,9,10 The incidence of congenital transmission
increases with each trimester and may be as high as 80% in the third trimester.11
However, the manifestations tend to be more severe the earlier in pregnancy the
infection is acquired by the mother.6,9,11-13 Sequelae can range from subclinical
manifestations to perinatal death, with most complications presenting months to
years after delivery.9,14 The characteristic triad of congenital toxoplasmosis is
hydrocephalus, cerebral calcifications, and retinochoroiditis.9,11
Ocular toxoplasmosis occurs in over 80% of congenital Toxoplasma infection, but
only 1% of patients with the acquired infection.7 However, serologic testing
suggests more cases may be attributed to the acquired form than originally
believed.4,7,13 Ocular toxoplasmosis is often diagnosed based on characteristic
retinal findings. Involvement of the macula or optic nerve may result in permanent
damage and visual impairment. Treatment is aimed at preserving macular and optic
nerve function.
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Case Report
A 22 year-old Caucasian female presented to the optometry service with acute
symptoms of hazy vision and a new gray stationary blind-spot in the inferior field
of vision of the right eye. She also was experiencing mild light sensitivity, but no
pain, flashes of light, or new floaters. Symptoms began approximately 3 days prior
and had been persistent. She denied a history of ocular trauma or surgery. The
patient had a history of ocular toxoplasmosis in the right eye at age 10 with
recurrence at age 16, resulting in chorioretinal scars adjacent to the optic nerve. She
was treated for the initial episode with clindamycin and oral prednisone at which
time she experienced a significant anaphylactic reaction to clindamycin. The patient
was 12 weeks pregnant when she presented for the most recent visit. Medical
history was negative for diabetes, hypertension, and HIV/AIDS. She was on no
medications and had a drug allergy to clindamycin.
The patient’s uncorrected visual acuities with a Snellen chart measured 20/40 OD
and 20/20 OS. Her visual acuity improved to 20/25-1 OD with pinhole testing.
Amsler grid testing was abnormal in the right eye with a relative scotoma inferior
to fixation. Her pupils were equal, round, reactive to light, and no afferent pupillary
defect was noted in either eye. The slit lamp examination of the anterior segment
showed multiple, fine keratic precipitates of the right cornea while the left cornea
was clear. The anterior chamber of the right eye revealed grade 2 cells while the
left eye was clear and quiet. The intraocular pressures were 15 mm Hg and 14 mm
Hg in the right and left eyes, respectively, as measured by Goldmann applanation
tonometry. A dilated fundus examination showed grade 3 cells throughout the
anterior and posterior vitreous of the right eye only. The nerves appeared healthy
with a cup-to-disc ratio of 0.15 and the retinal vessels showed normal course and
caliber in both eyes. The right fundus was slightly difficult to assess due to the haze
from the overlying vitritis. Two chorioretinal scars approximately 0.75DD and
0.50DD in size were noted within the superior temporal arcade adjacent to the right
optic nerve. A third small chorioretinal scar was found along the superior temporal
arcade of the right eye and adjacent to an elevated, white “fluffy” lesion with
surrounding retinal edema nearly 1DD in size. The macula of the right eye exhibited
an epiretinal membrane with traction toward the old chorioretinal scars, likely
secondary to the contracting forces of the scar tissue (Figure 1). The peripheral
retina was flat and intact 360 degrees in both eyes.
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Figure 1. Fundus of the right eye at initial presentation exhibiting chorioretinal scars adjacent to the
optic nerve, an epiretinal membrane with macular involvement, and an active toxoplasmosis lesion
along the superior temporal arcade with an overlying vitritis.

The patient’s history of ocular toxoplasmosis and classic clinical presentation led
to the diagnosis of reactivated ocular toxoplasmosis during pregnancy. The patient
was instructed to begin sulfamethoxazole/trimethoprim 800/160 mg by mouth
twice daily. Due to the inflammatory spillover, prednisolone acetate 1% suspension
every hour and scopolamine twice daily were prescribed for the anterior chamber
reaction in the right eye. The patient was educated on the importance of adherence
with the medical regimen and risk of vision loss. She was also instructed to monitor
vision with an Amsler grid daily and call immediately if any changes occurred. The
patient was to return to the clinic in 2 days for follow-up and consideration to begin
oral prednisone.
The patient returned to the clinic 3 days later, having followed the medication
regimen as prescribed. The hazy vision and stationary gray blind-spot in the inferior
visual field of the right eye were stable. Her visual acuities remained correctable to
20/25-1 OD and 20/20 OS. The relative scotoma inferior to fixation was still present
on the Amsler grid, but seemed less dark to the patient. Her right pupil was
pharmacologically dilated and no afferent pupillary defect was noted in either eye
on reverse testing. The anterior segment evaluation of the right eye was unchanged,
with fine keratic precipitates of the cornea and grade 2 cells in the anterior chamber.
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Grade 3 cells were present throughout the right vitreous. The chorioretinal scars
along the superior temporal arcade and the epiretinal membrane in the right eye
were stable. No changes were noted in the elevated white “fluffy” lesion adjacent
to the small chorioretinal scar. The patient was instructed to continue
sulfamethoxazole/trimethoprim 800/160 mg by mouth twice daily, prednisolone
acetate 1% every hour and scopolamine twice daily in the affected eye. She was to
continue daily monitoring of an Amsler grid and return to the clinic in 4 days.
One week after the initial visit the patient noted a subjective improvement in the
vision of her right eye. She stated the stationary blind-spot inferiorly in that eye was
smaller, less dark, and now described as a small brown spot. Her uncorrected
distance visual acuities were 20/25-1 OD without improvement with pinhole testing
and 20/20 OS. The relative scotoma inferiorly in the right eye with the Amsler grid
appeared smaller and less dense. The affected corneal keratic precipitates had
resolved and the anterior chamber reaction was improved with trace cells noted.
The dilated fundus exam revealed grade 2 vitritis in the right eye. The old
chorioretinal scars and epiretinal membrane were stable. The elevated white
“fluffy” lesion in the right eye appeared slightly smaller with less surrounding
retinal edema (Figure 2). The patient was instructed to continue
sulfamethoxazole/trimethoprim 800/160 mg by mouth twice daily, scopolamine
twice daily, and reduce prednisolone acetate 1% suspension to every 2 hours in the
affected eye. She was to continue daily monitoring of an Amsler grid and return to
the clinic in 1 week.

Figure 2. Fundus of the right eye 1 week after initiation of antibacterial therapy. Slight improvement
is noted in the active toxoplasmosis lesion and overlying vitritis.
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At 2 weeks, clinical and subjective findings remained relatively stable. The
prednisolone acetate 1% suspension was reduced to 4 times per day, otherwise the
medication regimen was continued. The patient noted further subjective visual
improvement in the right eye at the 3-week follow-up examination. She stated her
vision was no longer hazy and the inferior relative scotoma with the Amsler grid
was still present, but “faded.” Her best corrected visual acuities were 20/25+1 OD
and 20/20 OS. The vision in her right eye was likely reduced secondary to the
longstanding epiretinal membrane. The right eye anterior chamber reaction was
resolved. The dilated fundus examination showed marked improvement of the
posterior segment inflammation in the right eye. The vitreous haze was minimal
with trace cells in the posterior chamber. The active lesion in the right eye was still
elevated, but smaller with minimal surrounding retinal edema (Figure 3). The
patient was instructed to continue sulfamethoxazole/trimethoprim 800/160 mg by
mouth twice daily, taper prednisolone acetate 1% suspension as directed (three
times per day for 1 week, then twice daily for 1 week, and once daily for 1 week),
and discontinue scopolamine. She was instructed to monitor an Amsler grid daily
and return to the clinic in 2 weeks.

Figure 3. Fundus of the right eye comparing appearance at initial presentation (left) to appearance
after 21 days of antibiotic therapy (right). Marked improvement in retinal lesion, overlying vititris,
and patient symptoms were noted.

The patient returned to the clinic 2 weeks later (5 weeks after the initial visit). She
was taking sulfamethoxazole/trimethoprim 800/160 mg by mouth twice daily and
prednisolone acetate 1% suspension twice daily in the right eye with good
adherence. She stated vision was “back to normal.” The inferior scotoma of the
right eye was stable. The visual acuities remained 20/25+1 with +0.25 sphere OD
and 20/20 uncorrected OS. The anterior chamber was clear and quiet in each eye.
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The dilated fundus examination in her right eye showed a resolution of the vitritis.
The active toxoplasmosis lesion in the affected eye was dull white with minimal
elevation and no surrounding edema. The patient was instructed to continue
sulfamethoxazole/trimethoprim 800/160 mg by mouth twice daily for 1 week and
then discontinue usage. She was to finish the prednisolone acetate 1% suspension
taper with once daily dosing for 1 week and then discontinue usage. Education was
provided to the patient regarding resolution of ocular findings and future signs,
symptoms, and risk factors for recurrence of ocular toxoplasmosis. She was to
return to the clinic in 4 months for follow-up.
DISCUSSION
Toxoplasmosis is a parasitic infection that affects over 2.5 billion people in the
world.1,4,5 It has been estimated that half the United States population are
seropositive for Toxoplasma antibodies by the fourth decade. However, data
suggests the prevalence has been on the decline, with approximately 14%
seropositivity amongst individuals by 40 years of age.2,15 Toxoplasma gondii
accounts for the most cases of infectious posterior uveitis and may result in
visual impairment.8,16.17
In ocular toxoplasmosis, active tachyzoites enter retinal cells causing a focal
necrotizing retinochoroiditis resulting in an elevated, white “fluffy” lesion of the
inner retinal layers with surrounding edema. The release of inflammatory cells and
Toxoplasma antigens into the vitreous yield an overlying vitritis in virtually all
cases.4,6-8,10,12,13,17,18 Ocular toxoplasmosis is first noted between 15 and 35 years of
age in 60% of cases and occurs bilaterally in 22 to 40% of all
cases.7-19 When transmitted congenitally, it is more often bilateral (85%) and has a
higher predilection for the macula (58%).19 Reactivation of the ocular infection
occurs in 79% of cases within 5 years, with an average of 3 recurrences. It is most
likely to reactivate within the first year of an active retinal infection.4,7,18,19 The
retinochoroiditis often recurs adjacent to inactive, pigmented scars and is believed
to be due to the rupture of retinal cysts lying dormant near the location of prior
infection.
Active retinochoroiditis from ocular toxoplasmosis causes symptoms in 90% of
cases.7 Symptoms may include floaters, photopsia, metamorphopsia, reduced
vision, or visual field loss. Secondary complications occur in 33% of patients
including anterior segment inflammation, cataract, secondary glaucoma, retinal
vasculitis, choroidal neovascularization, retinochoroid vascular anastomoses
(ciliary retinal shunt vessels), neuroretinitis, retinal detachment, and papillitis with
secondary optic atrophy.4,7,16 Severity of symptoms and visual impairment are
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directly related to macular or optic nerve involvement and degree of vitritis. The
long-term prognosis for nearly 25% of patients with ocular toxoplasmosis is best
corrected visual acuity worse than 20/200 in at least one eye.19
Ocular toxoplasmosis is often diagnosed based on the characteristic focal
necrotizing retinochoroiditis with overlying vitritis, or “headlight in the fog”
appearance.4,13 The differential diagnosis for ocular toxoplasmosis includes ocular
histoplasmosis, sarcoidosis, tuberculosis, syphilis, ocular toxocariasis, fungal
infection, cytomegalovirus, and a focal retinoblastoma in infants. The classic
appearance, the presence of adjacent, inactive chorioretinal scars, and the prior
history of ocular toxoplasmosis enabled the diagnosis of reactivated ocular
toxoplasmosis to be made with confidence in this case. When the etiology is less
clear, serological or molecular testing may be used to aid in diagnosis.
Toxoplasmosis acquired by an immunocompetent individual is often self-limiting
and rarely requires treatment. Treatment is required for an acquired infection in the
immunocompromised patient, pregnant women with suspected or confirmed
primary Toxoplasma gondii infection, and any case of congenital toxoplasmosis
regardless of symptoms.11 Active retinochoroiditis is typically another indication
for treatment, as demonstrated in our patient. Providers may elect not to treat small,
peripheral retinal lesions that are at low risk for visual complications and may
resolve without intervention. However, treatment is required when active lesions
are threatening the macula, papillomacular bundle or optic nerve, grade 3 or greater
vitritis, infection lasting longer than 1 month, reduced vision, lesions greater than
1DD in size, or threat of a retinal detachment.7,13,16,18 The goal of treatment for
ocular toxoplasmosis is primarily to preserve the integrity and function of the
macula and optic nerve.
In our case, the immunocompetent patient was 12 weeks pregnant with a
reactivation of a chronic ocular toxoplasmosis infection with risk to her vision.
Pregnant women who acquire the infection prior to pregnancy are not at risk for
transmission to the fetus or future offspring.
The mother develops permanent immunity through antibodies to the primary
infection, and therefore protects the unborn child.7,9,11,13,14,20 Although there have
been some documented cases of reactivation of a chronic infection transmitted to
the fetus, this is quite rare. This most often happens in a female that is
immunocompromised from conditions such as organ transplant therapies or
acquired immunodeficiency syndrome.9,11,14 It was important to consider a
treatment regimen that was effective and safe for both mother and unborn child.
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The classic triple therapy for toxoplasmosis is pyrimethamine, sulfadiazine, and
oral prednisone. The regimen consists of a loading dose of 75 to 100 mg of
pyrimethamine daily for two days, followed by 25 to 50 mg daily and a 2-gram
loading dose of sulfadiazine, followed by 1 gram every six hours as well as 5 mg
of folinic acid daily for four to six weeks. Oral prednisone 20 to 80 mg daily may
be started the second to third day of therapy and tapered over two to six weeks.
However, treatment regimens may vary due to limited clinical studies and
significant side effects of the medications.16,17,21 Pyrimethamine is contraindicated
in the first 18 weeks of pregnancy due to the risk of teratogenic effects on the fetus.
It may cause bone marrow suppression due to folate antagonism, requiring close
monitoring of blood counts and co-administration of folinic acid. Sulfadiazine
requires high fluid intake to prevent renal crystallization and some individuals may
experience a severe allergic reaction to this sulfa medication. Use of oral
corticosteroids is controversial, and many questions remain unanswered such as the
additive benefit versus anti-parasitic treatment alone, dosage, when to initiate the
treatment regimen, and duration of treatment.16,22 Further research is required to
determine their benefit in cases of toxoplasmosis.
Alternative medications for ocular toxoplasmosis noted in the literature include
clindamycin,
spiramycin,
sulfamethoxazole/trimethoprim,
azithromycin,
minocycline, clarithromycin, and atovaquone. Clindamycin has shown to be an
effective treatment either as monotherapy or combined with the classic triple
therapy.7,23 A small randomized clinical trial suggested intravitreal injection of
clindamycin and dexamethasone may also be an acceptable alternative to triple oral
therapy for ocular toxoplasmosis.4,23,24 The injection therapy showed good efficacy
and may be more convenient and provide better drug availability while providing
less medication side effects, adherence complications, hematologic monitoring, and
potentially fewer follow-up visits.4,23 It may be a good alternative when oral
medications are contraindicated or do not provide an adequate response.24
Treatment regimen during pregnancy is dependent on when the Toxoplasma
infection was acquired. Spiramycin, not commercially available in the United
States, is recommended for pregnant women with primary infection before 18
weeks gestation to decrease the risk of Toxoplasma gondii transmission to the
fetus.9,11,14,16,18 Medication may be switched to triple therapy to treat fetal infection
confirmed by a positive polymerase chain reaction of amniotic fluid or acute
maternal infection only after 18 weeks, due to the teratogenic risk of
pyrimethamine.9,11,14 New findings suggest spiramycin combined with
sulfamethoxazole/trimethoprim may have superior efficacy to spiramycin alone in
preventing fetal transmission.25 This combination was also found to be at least as
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effective as pyrimethamine/sulfadiazine, proving a good alternative to classic
therapy, especially during pregnancy.25
In our case, the patient had a reactivation of her chronic infection and was not
immunocompromised. Therefore, no risk of transmitting the Toxoplasma infection
to the fetus was present. Treatment was still required due to her symptomatic
reactivation and threat to vision. Because of the pyrimethamine contraindication
during pregnancy, previous allergic response to clindamycin, and lack of
spiramycin availability in the United States, the alternative treatment of
sulfamethoxazole/trimethoprim 800/160 mg by mouth twice daily for 6 weeks was
initiated. Sulfamethoxazole/trimethoprim alone was shown to be an effective
alternative to the classic triple therapy in a randomized clinical trial and
uncontrolled case series.5,26,27 Another study suggested recurrences of
retinochoroiditis were reduced with intermittent, long-term dosing of
sulfamethoxazole/trimethoprim.7,28 It is first line treatment in many low income
countries due to availability and low cost when compared to pyrimethamine.5
Prednisolone acetate 1% and scopolamine were added to treat the secondary
anterior chamber reaction and tapered appropriately. Oral corticosteroids were not
added as the patient’s clinical course continued to improve with antibiotic treatment
alone.
Prevention is the key to reducing the prevalence of infection from Toxoplasma
gondii. Preventative measures include adequately cooking meat, washing fruits and
vegetables, and avoiding unpasteurized milk. Contaminated water has been an
increasingly recognized source of infection. Thorough hand washing should occur
after contact with raw meats/vegetables, cats, litter boxes, and contaminated soils.
Litter boxes should be cleaned daily to prevent sporulation. Pregnant women who
are seronegative for Toxoplasma antibodies should avoid contact with cats, litter
boxes, or potentially contaminated soil and other surfaces during pregnancy. Sand
boxes should be covered when not being used. Transmission during blood
transfusions or organ transplantations are rare, however, seropositive donors should
be avoided.
CONCLUSION
Toxoplasmosis is a common parasitic infection throughout the world and
continues to be a life-threatening condition in the infant or immunocompromised
individual. Ocular toxoplasmosis is the leading cause of retinochoroiditis and has
the potential to cause irreversible ocular damage and visual impairment. There
continues to be a lack of consensus on treatment, and further research is required to
determine a safe and effective treatment regimen. Utilizing preventative measures
remains critical to reducing future transmission of Toxoplasma gondii.
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In our case, the patient was in her first trimester of pregnancy and therefore careful
consideration needed to be made regarding the risk of congenital transmission and
safe treatment options. The patient responded well to an alternative antibiotic
therapy without the need for oral corticosteroids and she continued to have a healthy
pregnancy.
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